An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds

The cholinergic system is involved in cognitive processes such as attention, memory and learning (Jones et al., 1999, Terry et al., 2003, Levin et al., 2006, Nees, 2015) and it holds promise as a therapeutic target due to its role in the pathophysiology of neurodegenerative and psychiatric disorders (Court et al., 2000, Sacco et al., 2004, Parri et al., 2011). Hence, anti-cholinergic pharmacological challenges have been used to induce temporary cognitive disturbances mimicking Alzheimer's disease (AD), scopolamine being the most frequently used challenge drug.

https://ift.tt/2Nv4rnm